AOC 1044, Sodium Chloride 0.9% w/v clinical trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping

This study is testing a new medicine, AOC 1044, for boys and men with Duchenne muscular dystrophy (DMD) who have a specific genetic change. It compares the new medicine to a harmless substance (placebo) to see if it's safe and helps improve muscle function.